Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
03 September 2020 London, UK and Paris, France Pre-clinical studies show promising safety and immunogenicity Over 400 participants being enrolled...
